Literature DB >> 10951282

Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells.

N A Kukutsch1, S Rossner, J M Austyn, G Schuler, M B Lutz.   

Abstract

Dendritic cells (DC) are professional antigen-presenting cells that are able to induce primary T cell responses. Therefore, several strategies employ peptide-pulsed DC in tumor immunotherapy. For efficient antigen presentation and induction of an immune response by DC the number and stability of MHC I-peptide complexes is crucial. We studied this issue by using the antibody 25-D1.16 that specifically detects OVA peptide SIINFEKL in conjunction with H-2 Kb molecules, and determined its kinetics on mature and immature bone marrow-derived murine DC. Optimal peptide loading was reached after 8-16 h at 50 microM peptide pulse, and was comparable in serum-free versus serum-containing medium. Stimulation of DC with LPS or Poly I:C, and to a lesser extent TNF-alpha, upregulated the total number of surface MHC I molecules and thus improved peptide loading. Pulse-chase experiments revealed a constant half-life of peptide/Kb complexes independent of preceding DC stimulation or their maturation stage. The duration of peptide/Kb complex expression on mature DC, however, could be extended from 24 h to 72 h when the cultures were pretreated with LPS or Poly I:C, but not TNF-alpha. These data might have important implications for the clinical application of peptide-pulsed DC in tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951282     DOI: 10.1046/j.1523-1747.2000.00084.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

Review 1.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  Cellular uptake followed by class I MHC presentation of some exogenous peptides contributes to T cell stimulatory capacity.

Authors:  Susan E Brophy; Lindsay L Jones; Phillip D Holler; David M Kranz
Journal:  Mol Immunol       Date:  2006-12-12       Impact factor: 4.407

3.  Using intein catalysis to probe the origin of major histocompatibility complex class I-presented peptides.

Authors:  Diego J Farfán-Arribas; Lawrence J Stern; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-01       Impact factor: 11.205

4.  Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation.

Authors:  Nicole L Yates; Martha A Alexander-Miller
Journal:  Virology       Date:  2006-10-20       Impact factor: 3.616

5.  Langerhans cells cross-present antigen derived from skin.

Authors:  Patrizia Stoitzner; Christoph H Tripp; Andreas Eberhart; Kylie M Price; Jae Y Jung; Laura Bursch; Franca Ronchese; Nikolaus Romani
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-03       Impact factor: 11.205

6.  Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe.

Authors:  Breanna L Zerfas; Darci J Trader
Journal:  J Am Chem Soc       Date:  2019-03-20       Impact factor: 15.419

7.  DNA Dendrons as Agents for Intracellular Delivery.

Authors:  Max E Distler; Michelle H Teplensky; Katherine E Bujold; Caroline D Kusmierz; Michael Evangelopoulos; Chad A Mirkin
Journal:  J Am Chem Soc       Date:  2021-08-19       Impact factor: 16.383

8.  Biomechanical forces enhance directed migration and activation of bone marrow-derived dendritic cells.

Authors:  Ji-Hun Kang; Hyun Joo Lee; Ok-Hyeon Kim; Yong Ju Yun; Young-Jin Seo; Hyun Jung Lee
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

Review 9.  T cells as vehicles for cancer vaccination.

Authors:  Adham S Bear; Conrad R Cruz; Aaron E Foster
Journal:  J Biomed Biotechnol       Date:  2011-10-27

10.  Cross-presentation: how to get there - or how to get the ER.

Authors:  Christoph Kreer; Judith Rauen; Matthias Zehner; Sven Burgdorf
Journal:  Front Immunol       Date:  2012-01-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.